Getinge (OTCMKTS:GNGBY) Sets New 52-Week High – Still a Buy?

Getinge (OTCMKTS:GNGBY)’s share price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $25.24 and last traded at $25.24, with a volume of 402 shares trading hands. The stock had previously closed at $25.1550.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised shares of Getinge from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Strong Buy”.

Getinge Trading Up 2.5%

The business’s 50 day simple moving average is $22.61 and its two-hundred day simple moving average is $21.50. The stock has a market cap of $7.03 billion, a P/E ratio of 24.57 and a beta of 0.92. The company has a quick ratio of 0.74, a current ratio of 1.31 and a debt-to-equity ratio of 0.26.

Getinge (OTCMKTS:GNGBY) last announced its quarterly earnings results on Friday, July 17th. The company reported $0.38 EPS for the quarter. Getinge had a return on equity of 11.12% and a net margin of 7.81%.The company had revenue of $894.87 million during the quarter. As a group, analysts expect that Getinge will post 1.38 EPS for the current year.

About Getinge

Getinge AB is a global medical technology company that develops, manufactures and markets products and systems for hospitals and life sciences institutions. The company’s offerings focus on critical care, surgical workflows and infection control, aiming to improve clinical outcomes and operational efficiency. Getinge’s solutions support a range of applications from intensive care and cardiovascular treatments to sterile reprocessing of surgical instruments.

The company’s product portfolio includes sterilization and disinfection equipment, surgical tables and lights, ventilation systems, heart-lung machines and extracorporeal membrane oxygenation (ECMO) devices.